open access

Vol 76, No 6 (2018)
Short communications
Published online: 2018-06-11
Submitted: 2017-08-29
Accepted: 2018-02-15
Get Citation

Dysregulations of miRNAs and galectin-3 may underlie left ventricular dilatation in patients with systolic heart failure

Mariusz Tomaniak, Grażyna Sygitowicz, Krzysztof J. Filipiak, Olga Błaszczyk, Łukasz Kołtowski, Aleksandra Gąsecka, Janusz Kochanowski, Dariusz Sitkiewicz
DOI: 10.5603/KP.2018.0118
·
Kardiol Pol 2018;76(6):1012-1014.

open access

Vol 76, No 6 (2018)
Short communications
Published online: 2018-06-11
Submitted: 2017-08-29
Accepted: 2018-02-15

Abstract

Not available

Abstract

Not available
Get Citation
Supplementary Files (2)
Suppl. Fig.1. miR-1 (A.) and miR-21 (B.) expressions in patients with left ventricular end-diastolic diameter (LVEDD)>60mm (n=30) and LVEDD<60mm (n=29).
View
1MB
Suppl. Fig.2. Correlations between biochemical parameters and echocardiographic features in patients with significantly increased left ventricular end-diastolic diameter (n=30).
View
1MB
About this article
Title

Dysregulations of miRNAs and galectin-3 may underlie left ventricular dilatation in patients with systolic heart failure

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 76, No 6 (2018)

Pages

1012-1014

Published online

2018-06-11

DOI

10.5603/KP.2018.0118

Bibliographic record

Kardiol Pol 2018;76(6):1012-1014.

Authors

Mariusz Tomaniak
Grażyna Sygitowicz
Krzysztof J. Filipiak
Olga Błaszczyk
Łukasz Kołtowski
Aleksandra Gąsecka
Janusz Kochanowski
Dariusz Sitkiewicz

References (11)
  1. Artham SM, Lavie CJ, Milani RV, et al. Clinical impact of left ventricular hypertrophy and implications for regression. Prog Cardiovasc Dis. 2009; 52(2): 153–167.
  2. Barwari T, Joshi A, Mayr M. MicroRNAs in Cardiovascular Disease. J Am Coll Cardiol. 2016; 68(23): 2577–2584.
  3. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014; 42(Database issue): D68–D73.
  4. de Boer RA, Voors AA, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail. 2009; 11(9): 811–817.
  5. Shah RV, Chen-Tournoux AA, Picard MH, et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail. 2010; 12(8): 826–832.
  6. Abergel E, Chatellier G, Hagege AA, et al. Serial left ventricular adaptations in world-class professional cyclists: implications for disease screening and follow-up. J Am Coll Cardiol. 2004; 44(1): 144–149.
  7. Zhang R, Niu H, Ban T, et al. Elevated plasma microRNA-1 predicts heart failure after acute myocardial infarction. Int J Cardiol. 2013; 166(1): 259–260.
  8. Seronde MF, Vausort M, Gayat E, et al. Circulating microRNAs and Outcome in Patients with Acute Heart Failure. PLoS One. 2015; 10(11): e0142237.
  9. Dong S, Ma W, Hao B, et al. microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2. Int J Clin Exp Pathol. 2014; 7(2): 565–574.
  10. Tatsuguchi M, Seok HY, Callis TE, et al. Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol. 2007; 42(6): 1137–1141.
  11. McCullough PA, Olobatoke A, Vanhecke TE. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med. 2011; 12(4): 200–210.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl